Last edition
News about "pharmaceutical mergers and acquisitions"
Chiesi Group to Acquire KalVista Pharmaceuticals to Expand Rare Disease Portfolio
Chiesi Group to acquire KalVista Pharmaceuticals for USD 1.9 billion, adding an oral on-demand therapy for hereditary angioedema and strengthening its global rare disease portfolio, with closing expected in Q3 2026.
Pharmaceutical Mergers And Acquisitions | 30/04/2026 | By News Bureau
Gilead Sciences Completes Arcellx Inc. Acquisition Ahead of Anito-cel Launch
Under the terms of the transaction, Gilead acquired Arcellx for USD 115 per share in cash, plus one non?transferable Contingent Value Right (CVR) of USD 5 per share, representing a total implied equity value of approximately USD 7.8 billion at the time of closing.
Pharmaceutical Mergers And Acquisitions | 29/04/2026 | By News Bureau
IMG Pharma to Acquire Matsumoto Pharmaceutical
IMG Pharma signs a definitive agreement to acquire Matsumoto Pharmaceutical, combining biopharmaceutical innovation with manufacturing and OTC capabilities, forming a multi-layered product capability structure.
Pharmaceutical Mergers And Acquisitions | 28/04/2026 | By News Bureau
Neurocrine to Acquire Soleno Therapeutics
Neurocrine to acquire Soleno Therapeutics, adding US FDA-approved VYKAT XR for Prader-Willi Syndrome and strengthening its rare disease and endocrinology portfolio.
Pharmaceutical Mergers And Acquisitions | 07/04/2026 | By News Bureau
Gilead Extends Tender Offer to Acquire Arcellx
Gilead extends tender offer to acquire Arcellx until April 24, 2026, providing additional time for shareholders to participate in the proposed acquisition.
Pharmaceutical Mergers And Acquisitions | 02/04/2026 | By News Bureau | 128
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy